Orencia® (abatacept) 125mg solution for injection - New Formulation

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates> SPC Changes Bristol-Myers Squibb has been granted marketing authorisation for a new formulation given by subcutaneous injection.   Orencia® (abatacept) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a tumour necrosis factor-alpha inhibitor.   Please see link to SPC for full prescribing information.
Source: NeLM - SPC Changes - Category: Drugs & Pharmacology Source Type: news

Related Links:

A new study examines the impact of the initiation of disease-modifying therapies on blood pressure among patients with rheumatoid arthritis.Journal of Clinical Rheumatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Patient Presentation A 3.5-year-old female came to clinic with a 2-day history fever up to 101°F. The evening before she had complained of a sore throat but had no rhinorrhea, cough or rash. She was drinking reasonably well and was urinating frequently. She had been to a birthday party where an older child had had strep throat. The past medical history was positive for Kawasaki Disease diagnosed at 17 months of age and treated with intravenous immunoglobulin (IVIG) on day 6 of fever. Her echocardiograms had been negative and she was being appropriately monitored by cardiology. The family history was positive for heart...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
 A new study has gone further towards ensuring people living with both rheumatoid arthritis and mental health problems get the best treatment for them.Rheumatoid arthritis affects the whole body, but we know that it can also have an impact on a person’s mental health. Around a third of the 400,000 people in the UK with rheumatoid arthritis also experience mental health issues. This compares to around 1 in 4 people in the general population.The way rheumatoid arthritis is treated was revolutionised by the discovery of anti-TNF drugs– now widely used in medical practice. Better treatments have led to more pe...
Source: Arthritis Research UK - Category: Rheumatology Source Type: news
This study aimed at exploring the mechanism of HGT on RA using the bioinformatics analysis with in vivo and in vitro experiment validation. The potential action mechanism was first investigated by bioinformatics analysis via Ingenuity Pathway Analysis (IPA) software. After that, we use experimental validation such as collagen-induced arthritis (CIA) mice model in vivo and U937 cell model in vitro. The bioinformatics results suggested that HGT may have anti-inflammatory characteristic on RA and IL-12 signaling pathway could be the potential key trigger. In vivo experiments demonstrated that HGT ameliorated the symptoms in C...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
We present a case series of 11 patients with severe alopecia areata on longstanding, regular to high dose oral tofacitinib with marked hair regrowth. Additionally, we present a case of moderate to severe alopecia areata successfully treated with topical tofacitinib cream. J Drugs Dermatol. 2018;17(7):800-803. PMID: 30005104 [PubMed - in process]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
CONCLUSIONS: In high BMI RA patients both SJC and DAS28 seem to be undervalued by clinical assessment when compared to US. PMID: 29998844 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSIONS: The US scan of 3 target joints showed a high sensitivity in detecting subclinical active synovitis in RA patients in clinical remission and can be feasible in the routine assessment of these patients. PMID: 29998842 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSIONS: Over a 10-year follow-up period, reclassification revealed significant heterogeneity in the diagnosis of seronegative RA. Therefore, seronegative arthritis should not be studied as a homogenous entity. PMID: 29998832 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Authors: Watanabe T, Hattori T, Ogawa Y, Jodo S PMID: 29998828 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSIONS: IB was well-tolerated and comparable to IO, with no additional safety signals identified. The results suggest superior survival of IB over IO over the first 2 years. PMID: 29998827 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
More News: Abatacept | Arthritis | Databases & Libraries | Drugs & Pharmacology | Marketing | Methotrexate | Orencia | Rheumatoid Arthritis | Rheumatology